Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects.

ABSTRACT: Recent immunotherapy research has focused on chimeric antigen receptor-modified T cells (CAR-Ts). CAR-T therapies have been clinically applied to manage hematologic malignancies with satisfactory effectiveness. However, the application of CAR-T immunotherapy in solid tumors remains challenging. Even so, current CAR-T immunotherapies for prostate cancer (PCa) have shown some promise, giving hope to patients with advanced metastatic PCa. This review aimed to elucidate different types of prostate tumor-associated antigen targets, such as prostate-specific membrane antigen and prostate stem cell antigen, and their effects. The current status of the corresponding targets in clinical research through their applications was also discussed. To improve the efficacy of CAR-T immunotherapy, we addres

SUBMITTER: He M 

PROVIDER: S-EPMC10469587 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature